Alex Horchak, MD
Urology · Dubuque, IANPI 1033158209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,680 of the $8,274 with a category attached, or 68.6%. It is spread thinly across 20 manufacturers, the largest accounting for just 19.6%. Reporting peaked in 2019 at $2,217 and has fallen 75.7% since, to $539 in 2025.
Across 284 payments — averaging $29.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$2K
- Axonics, Inc.$2K
- Astellas Pharma US Inc$933
- Pfizer$828
- Coloplast$778
- Boston Scientific$699
- plus $2K from 14 others
What the payments were for
- Travel & lodging$2,15226%
- Food & beverage$5,68069%
- Education$4425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 7 | $1,625 |
| Axonics, Inc. | 45 | $1,573 |
| Astellas Pharma US Inc | 46 | $933 |
| Pfizer | 76 | $828 |
| Coloplast | 19 | $778 |
| Boston Scientific | 11 | $699 |
| Johnson & Johnson | 37 | $652 |
| Teleflex LLC | 8 | $422 |
| Tolmar, Inc. | 9 | $182 |
| AbbVie | 8 | $139 |
| 180 Medical, Inc. | 3 | $78 |
| Isoray, Inc | 1 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Urogen Pharma, Inc. | 2 | $53 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Bayer | 2 | $39 |
| Vertex | 2 | $37 |
| Caldera Medical, Inc | 1 | $29 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,422
- Bulkamid$674
- Axonics$674
- TITAN$317
- AMS 700 CXR RTE KIT$261
- UroLift System$141
- SPEEDICATH$128
- GENERAL ERECTILE DYSFUNCTION$117
- Axonics r-SNM System$116
- GENERAL BPH$114
How this compares
$8,274 in reported general payments places this provider in the 80th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 30 | $427,907 |
| XtandiEnzalutamide | 28 | $387,566 |
| MyrbetriqMirabegron | 349 | $214,683 |
| OrgovyxRelugolix | 45 | $121,648 |
| GemtesaVibegron | 44 | $24,020 |
| Tamsulosin Hcl | 856 | $20,358 |
| Oxybutynin Chloride ErOxybutynin Chloride | 251 | $6,396 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 274 | $6,254 |
| Finasteride | 373 | $5,583 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 40 | $3,732 |
| Mirabegron ErMirabegron | 12 | $3,693 |
| Silodosin | 51 | $3,162 |
| Dutasteride | 34 | $2,222 |
| Solifenacin Succinate | 75 | $1,923 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $1,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $933 | $602,249377 claims |
| Johnson & JohnsonErleada | $652 | $427,90730 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $64 | $145,66889 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 urology providers in Iowa.
Other urology in Dubuque
- Jaffer BasheyDubuque$6K
- Raymond RoeweDubuque$5K
- John DolehideDubuque$4K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
- Ryan DornbierClive$55K
- Alexandria HertzIowa City$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.